An experimental gene-editing therapy that aims to lower bad cholesterol for the long-term after a single infusion has shown promising results in an early clinical trial. In the Phase I safety trial for the drug, dubbed VERVE-102, researchers have observed a significant reduction of up to 62% in low-density lipoprotein (LDL), or 'bad' cholesterol levels among participants who received the highest dose.

The initial analysis, published in the New England Journal of Medicine, suggests that this reduction could potentially halve the risk of cardiovascular disease for individuals with high cholesterol over a period of 20 years. Although the trial is still in its early stages, it provides hope for a lasting solution to a common and often debilitating condition.

The gene-editing therapy works by using an mRNA-based design that delivers instructions to liver cells to make a specific base change in DNA. This change allows the cells to nick a single strand of DNA, targeting a gene involved in cholesterol metabolism. The nanoparticle delivery system ensures efficient uptake of the genetic material by the liver.

One of the most significant findings was a temporary increase in a liver enzyme linked to minor injury, indicating that while the therapy is showing promise, it may come with some side effects. However, the researchers reported no serious adverse events, and the LDL reductions have been sustained across all subgroups over the 18 months of follow-up data.

For now, this trial remains a small step in what could be a monumental leap towards permanent cholesterol reduction. The results are encouraging but require further validation through larger-scale studies before any definitive conclusions can be drawn.